What medications should be used for a breast mass, including management of a simple cyst, infection, and invasive breast cancer?

Medication Management for Breast Mass

Simple breast cysts require no medication—observation or aspiration only; breast infections are treated with antibiotics (typically dicloxacillin or cephalexin); and invasive breast cancer requires systemic therapy based on hormone receptor and HER2 status, with endocrine therapy for ER-positive disease and chemotherapy ± targeted agents for aggressive or receptor-negative tumors.

Simple Breast Cysts

No pharmacologic treatment is indicated for simple breast cysts. Simple cysts are benign (BI-RADS 2) and carry no increased risk of subsequent breast cancer development 1. Management options include:

• Routine screening if the cyst meets all ultrasound criteria for a simple cyst (anechoic, well-circumscribed, round/oval with imperceptible wall and posterior enhancement)
• Aspiration only if symptomatic or for patient reassurance
• Short-term follow-up (6-12 months) for complicated cysts that don't meet all simple cyst criteria but lack solid components

The key pitfall here is overtreatment—resist the urge to prescribe hormonal medications like danazol, which showed some benefit in older studies 2 but is not part of current standard practice. Simple cysts are a normal finding and do not require intervention unless symptomatic.

Breast Infection (Mastitis/Abscess)

Antibiotics are the primary pharmacologic treatment for breast infections. While the provided guidelines don't specify antibiotic regimens, standard practice includes:

• Puerperal mastitis (postpartum): Often diagnosed clinically without imaging, treated with antibiotics covering Staphylococcus aureus (dicloxacillin, cephalexin, or clindamycin if penicillin-allergic)
• Non-puerperal mastitis: Same antibiotic coverage, but requires imaging to exclude abscess or malignancy mimics 3
• Breast abscess: Antibiotics plus drainage (aspiration or surgical)

The critical caveat is that non-puerperal mastitis can mimic inflammatory breast cancer—if there's no improvement with antibiotics within 1-2 weeks, biopsy is mandatory to exclude malignancy.

Invasive Breast Cancer

Medication selection depends on tumor biology, stage, and menopausal status. This requires a systematic approach:

Step 1: Determine Hormone Receptor and HER2 Status

All invasive breast cancers must be tested for ER, PR, and HER2 expression to guide therapy.

Step 2: Adjuvant Endocrine Therapy (for ER-positive disease)

Premenopausal women:

• Tamoxifen 20 mg daily for 5-10 years is the standard 4
• Add ovarian suppression (goserelin 3.6 mg subcutaneously monthly) for high-risk disease 4
• Contraindications: History of DVT, PE, stroke, TIA, pregnancy, or prolonged immobilization 5

Postmenopausal women:

• Aromatase inhibitors should be included at some point in the treatment course 4
• Options include:
  • Upfront AI: Anastrozole 1 mg daily or letrozole 2.5 mg daily for 5 years 4
  • Sequential approach: Tamoxifen for 2-3 years, then switch to exemestane 25 mg daily or anastrozole 1 mg daily 4
  • Extended therapy: Tamoxifen for 5 years, then letrozole 2.5 mg daily or anastrozole 4
• Aromatase inhibitors are superior to tamoxifen for disease-free survival in postmenopausal women 4
• Mandatory supplements: Vitamin D and calcium due to skeletal adverse effects 4

Step 3: Adjuvant Chemotherapy

Indications based on risk stratification:

• Intermediate/high-risk disease (node-positive, large tumors >2 cm, grade 2-3, HER2-positive, age <35) 4
• Regimens should include anthracyclines (doxorubicin, epirubicin) for at least 4 cycles 4
• Add taxanes (paclitaxel, docetaxel) for high-risk patients, especially ER-negative disease 4

Common regimens include AC/T (doxorubicin/cyclophosphamide followed by taxane), FEC/D (fluorouracil/epirubicin/cyclophosphamide followed by docetaxel), or DAC (docetaxel/doxorubicin/cyclophosphamide) 4.

Timing: When combining chemotherapy with tamoxifen, start tamoxifen after chemotherapy completion 4. The timing of aromatase inhibitors with chemotherapy is less clear.

Step 4: HER2-Targeted Therapy

For HER2-positive disease (3+ by IHC or amplified by FISH):

• Trastuzumab is standard, given for up to 1 year 6
• Add pertuzumab for node-positive disease 6
• Do not give trastuzumab concurrently with anthracyclines due to cardiotoxicity 4, 6
• Monitor cardiac function (LVEF) before and every 3 months during therapy 6

Step 5: Metastatic/Recurrent Disease

Hormone receptor-positive:

• Start with endocrine therapy unless visceral crisis requires rapid response 7
• Premenopausal: Tamoxifen + ovarian ablation (LHRH analog, surgery, or radiation) 7
• Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) are superior to tamoxifen for response rate and time to progression 7
• Second-line options: Fulvestrant, megestrol acetate, alternative aromatase inhibitors 7

Hormone receptor-negative or endocrine-resistant:

• Chemotherapy is required 7
• Single agents (anthracyclines, taxanes, capecitabine, vinorelbine, gemcitabine) or combination regimens 7
• No single regimen is superior—choice based on prior treatments, toxicity profile, and patient preference 7

HER2-positive metastatic:

• Trastuzumab with or without chemotherapy (non-anthracycline-containing) 7
• Cardiac monitoring mandatory 7

Bone metastases:

• Bisphosphonates for hypercalcemia and palliation of lytic lesions 7

Critical Pitfalls to Avoid

1. Never use aromatase inhibitors alone in premenopausal women—they are ineffective without ovarian suppression 4
2. Don't combine tamoxifen with hormone replacement therapy 5
3. Avoid concurrent anthracyclines and trastuzumab—severe cardiotoxicity risk 4, 6
4. Don't skip cardiac monitoring with trastuzumab—check LVEF before and every 3 months 6
5. Workup abnormal vaginal bleeding promptly in tamoxifen users—endometrial cancer risk 5
6. Ensure concordance between pathology, imaging, and clinical findings before finalizing treatment plans 1